Prognostic significance of CD25 expression in dogs with a noninvasive diagnosis of B‐cell lymphoma treated with CHOP chemotherapy. (4th October 2022)

• Record Type: Journal Article
• Authors: Sheng, Richard; Clarke, Dawn; Laver, Travis; Meichner, Kristina; Northrup, Nicole; Tarigo, Jaime
• Is Part Of: Veterinary and comparative oncology. Volume 21:Number 1(2023)
• Page Start: 28
• Page End: 35
• Publication Date: 2022-10-04
• Subjects: canine -- chemotherapy -- interleukin‐2 -- lymphosarcoma; Veterinary oncology -- Periodicals; Neoplasms -- veterinary -- Periodicals; 636.0896994005
• DOI: 10.1111/vco.12857
• Languages: English
• ISSNs: 1476-5810

Abstract

Abstract: Prior studies have identified high CD25 expression in canine diffuse large B‐cell lymphoma as a negative prognostic indicator. The objective of this retrospective study was to evaluate CD25 expression as a prognostic indicator in dogs with B‐cell lymphoma (BCL) diagnosed with commonly used noninvasive diagnostics (cytology and flow cytometry [FC]) and treated with CHOP chemotherapy. Lymph node aspirates from 57 dogs with cytologic diagnosis of lymphoma composed of intermediate to large lymphocytes were analysed with FC. Percentage of neoplastic B‐cells expressing CD25 and median fluorescence intensity (MFI) of CD25 were measured. Relationships of CD25 percent positivity and MFI to progression free survival (PFS) and survival time were evaluated. Median survival time (MST) of all dogs was 272 days (95% CI, 196–348 days) and median PFS was 196 days (95% CI, 172–220 days). Higher percentage of B‐cells positive for CD25 was associated with decreased risk of death in multivariable analysis ( p = .02). Dogs with higher CD25 positivity had longer MST and PFS than dogs with lower CD25 positivity (318 days versus 176 days and 212 days versus 148 days, respectively), but these differences were not significant. CD25 MFI was not significantly associated with outcome. Based on the results of this study, the association of CD25 expression and prognosis in dogs with BCL diagnosed using noninvasive methods should be interpreted with caution. Further evaluation, with studies that include histopathologic differentiation of lymphoma subtypes, is needed.